- Home
- TXMD vs SABS Comparison
TXMD vs SABS Comparison
Compare TXMD & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- SABS
- Stock Information
- Founded
- TXMD 2008
- SABS 2014
- Country
- TXMD United States
- SABS United States
- Employees
- TXMD N/A
- SABS N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- SABS Health Care
- Exchange
- TXMD Nasdaq
- SABS Nasdaq
- Market Cap
- TXMD 13.5M
- SABS 15.8M
- IPO Year
- TXMD N/A
- SABS N/A
- Fundamental
- Price
- TXMD $1.14
- SABS $2.75
- Analyst Decision
- TXMD
- SABS Strong Buy
- Analyst Count
- TXMD 0
- SABS 5
- Target Price
- TXMD N/A
- SABS $11.80
- AVG Volume (30 Days)
- TXMD 30.4K
- SABS 37.3K
- Earning Date
- TXMD 07-30-2025
- SABS 08-07-2025
- Dividend Yield
- TXMD N/A
- SABS N/A
- EPS Growth
- TXMD N/A
- SABS N/A
- EPS
- TXMD N/A
- SABS N/A
- Revenue
- TXMD $1,841,000.00
- SABS $377,835.00
- Revenue This Year
- TXMD $427.09
- SABS N/A
- Revenue Next Year
- TXMD N/A
- SABS N/A
- P/E Ratio
- TXMD N/A
- SABS N/A
- Revenue Growth
- TXMD 53.55
- SABS N/A
- 52 Week Low
- TXMD $0.70
- SABS $1.00
- 52 Week High
- TXMD $2.44
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- TXMD 43.84
- SABS 75.33
- Support Level
- TXMD $1.07
- SABS $2.31
- Resistance Level
- TXMD $1.24
- SABS $2.98
- Average True Range (ATR)
- TXMD 0.08
- SABS 0.24
- MACD
- TXMD 0.00
- SABS 0.09
- Stochastic Oscillator
- TXMD 59.62
- SABS 89.31
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.